Log In
Print this Print this

Sylvant, siltuximab (CNTO 328)

  Manage Alerts
Collapse Summary General Information
Company Johnson & Johnson
DescriptionChimeric mAb against IL-6
Molecular Target Interleukin-6 (IL-6)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today